Zitat von RichyBerlin: Mal sehen wie sich das auf die zukünftigen Verkaufszahlen von Tremfya auswirkt

"August 14, 2019 07:12 AM EDT Amber Tong R&DPharma
Eli Lil­ly's Taltz beats J&J's Trem­fya in pso­ri­a­sis head-to-head — but the mar­ket­ing brawl is just be­gin­ning

Eli Lil­ly has come out swing­ing at J&J, stak­ing out its chal­lenger po­si­tion in a crowd­ed bat­tle of plaque pso­ri­a­sis block­busters.

In a Phase IV head-to-head study with 1,027 pa­tients, Lil­ly says its IL-17A in­hibitor Taltz beat J&J’s IL-23/p19 drug Trem­fya on com­plete skin clear­ance at week 12 as de­fined by PASI 100..."
https://endpts.com/eli-lillys-taltz-beats-jjs-tremfya-in-pso…

"...Cosentyx, also an IL-17 drug, has accrued $1.6 so far this year. In comparison, Taltz — which was first approved in 2016, a year later than Cosentyx — has scored $606.5 million, while Tremfya (approved yet another year later) counted $452 million..."